Initial real-world experience with iStent inject® trabecular micro-bypass stents in combination with cataract surgery

Session Details

Session Title: Microinvasive Glaucoma Surgery

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 14:42

Venue: Free Paper Forum: Podium 4

First Author: : E.Liang USA

Co Author(s): :                                 

Abstract Details

Purpose:

iStent inject® trabecular micro-bypass stents were recently introduced to the US surgeons and parts of the EU including France. This case series aims to evaluate early safety and performance of iStent inject implanted in patients with mild-to-moderate glaucoma also requiring concomitant cataract surgery.

Setting:

Single-center, single-surgeon, prospective clinical case series

Methods:

A retrospective case review of all consecutive cases from a single comprehensive ophthalmologist was conducted. Outcome measures included preoperative and postoperative intraocular pressure (IOP), glaucoma medication usage, visual fields, intraoperative and postoperative complications and other standard safety ophthalmological assessments. The surgeon intends to continue tracking patients on an ongoing basis to increase the sample size and also to report longer-term follow-up outcomes.

Results:

To date, 37 patients have been successfully implanted with iStent inject in combination with cataract surgery. Mean preoperative IOP was 17.95±5.61 mmHg on a mean of 1.05±0.91 medications. At 1 month postoperative, mean IOP was 16.17±6.31 mmHg (n=29). At 3 months, mean IOP was 12.00±1.91 mmHg (n=7). Medication burden remained unchanged as the surgeon typically does not adjust glaucoma medications until several months post-surgery. There were no notable intraoperative or postoperative complications. Safety, IOP, and medications will continue to be tracked with the intent to present a larger sample size with longer follow-up by the time of presentation.

Conclusions:

Early experience with iStent inject (2nd generation trabecular micro-bypass stents) demonstrated IOP reduction with a good safety profile. Ease of use as part of a combined procedure with cataract surgery was noted by the surgeon. iStent inject is a promising novel modality to surgically manage patients with glaucoma in a safe manner consistent with cataract surgery alone.

Financial Disclosure:

research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented